(Reuters) - Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that target so-called superbugs. Merck and British rival AstraZeneca Plc have turned their attention to newer kinds of antibiotics that attack superbugs - strains of bacteria that are resistant to several types of antibiotics - after the 2013 threat report from the U.S. Centers for Disease Control and Prevention. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment